Argenica Therapeutics Ltd stock analysis
Want to see AU:AGN full AI Analyst Report?
Argenica Therapeutics Ltd (AGN) Share Price & Analysis
AGN Stock Chart & Stats
- Day’s Range
- AUD 0.12 - AUD 0.13
- 52-Week Range
- AUD 0.09 - AUD 0.35
- Previous Close
- AUD 0.13
- Volume
- N/A
- Average Volume (3M)
- 58.38K
- Market Cap
- AUD 16.70M
- Enterprise Value
- AUD 32.86M
- Total Cash (Recent Filing)
- AUD 6.36M
- Total Debt (Recent Filing)
- AUD 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.48
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Zero debt limits leverage and refinancing pressure, giving Argenica greater flexibility while it advances its development programs. This can preserve strategic options and reduce fixed financial obligations, although the balance sheet remains exposed to operating losses and future funding needs.
Focused Neuroprotective Pipeline
A focused pipeline targeting serious neurological injuries gives Argenica a clear therapeutic purpose and aligns development resources around high-impact unmet needs. Progress in these programs could create meaningful product value if clinical development ultimately demonstrates improved outcomes.
Prior Revenue Expansion
The increase in reported revenue through 2025 indicates that Argenica had previously established some commercial or partnering activity before the 2026 interruption. That history provides evidence of potential revenue generation, though its durability remains unproven.
Bears Say
Persistent Operating Cash Burn
Sustained negative operating cash flow means the business is not funding its activities internally and remains reliant on available capital or future financing. Continued burn can reduce financial flexibility and may force funding decisions before development milestones are reached.
Revenue Volatility And Zero 2026 Revenue
The sharp revenue reversal demonstrates that reported income is highly volatile and that prior revenue growth has not yet become a dependable base. Unpredictable commercial inflows make planning harder and increase dependence on financing while the pipeline remains in development.
Recurring Losses And Weak Returns
Recurring operating and net losses show that Argenica has not yet reached sustainable profitability, while negative returns indicate shareholder capital is not currently producing earnings. This limits internally funded growth and leaves future value dependent on successful development and commercialization.
Argenica Therapeutics Ltd News
Argenica’s xaranetide concussion data earns international neurotrauma spotlight
Argenica Therapeutics Ltd ( ($AU:AGN) ) just unveiled an announcement. Argenica Therapeutics reported that preclinical data from its concussion program on xaranetide (ARG-007) have been selected for an oral presentation
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
What is Argenica Therapeutics Ltd’s market cap?
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
How were Argenica Therapeutics Ltd’s earnings last quarter?
Is Argenica Therapeutics Ltd overvalued?
Does Argenica Therapeutics Ltd pay dividends?
What is Argenica Therapeutics Ltd’s EPS estimate?
How many shares outstanding does Argenica Therapeutics Ltd have?
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
What is the TipRanks Smart Score and how is it calculated?
Argenica Therapeutics Ltd Stock Smart Score
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Liz Dallimore
- Employees
- 7
- Website
- argenica.com.au
- Address
- 117 Broadway, Nedlands, WA, 6009, AU
Argenica Therapeutics Ltd (AGN) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 4 | 0 | 8 |










